DB:AT2

Stock Analysis Report

Executive Summary

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Atara Biotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.0%

AT2

1.0%

DE Biotechs

1.4%

DE Market


1 Year Return

-62.7%

AT2

1.3%

DE Biotechs

3.8%

DE Market

Return vs Industry: AT2 underperformed the German Biotechs industry which returned 1.3% over the past year.

Return vs Market: AT2 underperformed the German Market which returned 3.8% over the past year.


Shareholder returns

AT2IndustryMarket
7 Day-6.0%1.0%1.4%
30 Day-20.0%-4.7%1.3%
90 Day-16.4%-4.6%3.1%
1 Year-62.7%-62.7%1.5%1.3%7.0%3.8%
3 Year-18.5%-18.5%67.3%65.6%18.5%8.3%
5 Year-4.5%-4.5%12.9%10.4%42.2%22.9%

Price Volatility Vs. Market

How volatile is Atara Biotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Atara Biotherapeutics undervalued compared to its fair value and its price relative to the market?

2.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: AT2 (€10.99) is trading above our estimate of fair value (€5.29)

Significantly Below Fair Value: AT2 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AT2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AT2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AT2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AT2 is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Atara Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

5.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AT2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AT2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AT2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AT2's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if AT2's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AT2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atara Biotherapeutics performed over the past 5 years?

-45.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AT2 is unprofitable, and losses have increased over the past 5 years at a rate of -45% per year.

Accelerating Growth: Unable to compare AT2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AT2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: AT2 has a negative Return on Equity (-120.1%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AT2 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AT2 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Atara Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AT2's short term assets ($201.1M) exceeds its short term liabilities ($25.8M)

Long Term Liabilities: AT2's short term assets (201.1M) exceeds its long term liabilities (16.1M)


Debt to Equity History and Analysis

Debt Level: AT2 is debt free.

Reducing Debt: AT2 had no debt 5 years ago.


Balance Sheet

Inventory Level: AT2 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AT2's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AT2 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AT2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -53.7% each year


Next Steps

Dividend

What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?

4.03%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Years4.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AT2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AT2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AT2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AT2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AT2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Atara Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Pascal Touchon (56yo)

0.3yrs

Tenure

0

Mr. Pascal Touchon has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019. He serves as Director of Cogen Therapeutics, Inc. since August 2018. He serve ...


Management Age and Tenure

1.3yrs

Average Tenure

49yo

Average Age

Experienced Management: AT2's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

56yo

Average Age

Experienced Board: AT2's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: AT2 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$43,19030 Sep 19
Joseph Newell
EntityIndividual
Role
Chief Technology Officer
Executive VP & Chief Technical Operations Officer
Shares3,500
Max PriceUS$12.34
BuyUS$34,31201 Jul 19
Eric Dobmeier
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,000
Max PriceUS$17.16
SellUS$675,64819 Mar 19
Alexandria Equities, LLC
EntityCompany
Shares20,000
Max PriceUS$33.78
SellUS$2,85101 Mar 19
Joel Marcus
EntityIndividual
Shares90
Max PriceUS$31.67
SellUS$316,82708 Nov 18
Joel Marcus
EntityIndividual
Shares10,000
Max PriceUS$31.68
SellUS$677,74408 Nov 18
Carol Gallagher
EntityIndividual
Role
Chairman of the Board
Chairman & Lead Independent Director
Shares21,374
Max PriceUS$31.71

Ownership Breakdown


Management Team

  • Renu Vaish (52yo)

    Senior Vice President of Global Regulatory Affairs

    • Tenure: 1.1yrs
  • Mina Kim (45yo)

    Senior VP of Corporate Strategy

    • Tenure: 1.5yrs
    • Compensation: US$3.47m
  • Steve Bertram

    Senior Vice President of Global Human Resources

    • Tenure: 3.2yrs
  • Joe Newell (49yo)

    Executive VP & Chief Technical Operations Officer

    • Tenure: 2.5yrs
    • Compensation: US$2.49m
  • John Craighead

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • AJ Joshi

    Senior VP & Chief Medical Officer

    • Tenure: 0yrs
  • Pascal Touchon (56yo)

    President

    • Tenure: 0.3yrs
  • Utpal Koppikar (49yo)

    Senior VP & CFO

    • Tenure: 1.3yrs
    • Compensation: US$4.22m
  • José Vidal

    Senior Vice President of Quality Assurance & Process Sciences

    • Tenure: 1.2yrs
  • Tim Valko

    Senior Vice President of Global Manufacturing & Supply Chain

    • Tenure: 0.6yrs

Board Members

  • Beth Seidenberg (62yo)

    Independent Director

    • Tenure: 7.2yrs
    • Compensation: US$246.76k
  • Eric Dobmeier (50yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$260.09k
  • Bill Heiden (59yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$246.76k
  • Matt Fust (54yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$261.76k
  • Carol Gallagher (54yo)

    Chairman & Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$269.26k
  • Roy Baynes (64yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$411.46k
  • Pascal Touchon (56yo)

    President

    • Tenure: 0.3yrs

Company Information

Atara Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atara Biotherapeutics, Inc.
  • Ticker: AT2
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$663.642m
  • Listing Market Cap: US$595.685m
  • Shares outstanding: 53.76m
  • Website: https://www.atarabio.com

Number of Employees


Location

  • Atara Biotherapeutics, Inc.
  • 611 Gateway Boulevard
  • Suite 900
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
AT2DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:36
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.